What is it about?
Relaxin may be an effective therapy in pulmonary fibrosis. However, if expression of the relaxin receptor RXFP1 is low, this might compromise the effectiveness of relaxin or relaxin-based therapies. We have found that in idiopathic pulmonary fibrosis (IPF), there is loss of RXFP1 expression. This loss of RXFP1 is accompanied by decreased sensitivity of fibroblasts to the effects of a relaxin-like peptide in vitro. The higher the expression of RXFP1 in the fibrotic lung, the better the pulmonary function.
Featured Image
Read the Original
This page is a summary of: Expression of RXFP1 is Decreased in Idiopathic Pulmonary Fibrosis: Implications for Relaxin-Based Therapies, American Review of Respiratory Disease, June 2016, American Thoracic Society,
DOI: 10.1164/rccm.201509-1865oc.
You can read the full text:
Contributors
The following have contributed to this page
